RM Global Health Inc.,has announced that it has reached an agreement with the Russian Company Vitafarma to acquire all list of pharmaceutical production, including newly and highly efficient vaccine against virus Herpes simplex
RMGH has a strong dealer network, and hospital focused service capabilities as well as cost effective manufacturing operations that all contribute significantly to its competitive position.
“Vitafarma has established a strong position in the Russian market, and is on track to growing further both within Russia and beyond. Becoming part of a global healthcare company is for us the perfect step to maximize this growth opportunity in a very interesting geographical market. We are very confident that we share the same culture, business goals and commitment to the market to make this happen. We have much to learn from each other, and much that can be leveraged between us,” said Dr. Ramaz Mitaishvili, CEO of RMGH.
Financial details were not disclosed.
Poor nations labor under the weight of viral and bacterial infections and a score of diseases lesser known in rich countries, but they cannot afford to pay the prices companies want for drugs. Whereas some might denounce the pharmaceutical industry’s profit seeking, RMGH wants to harness it. He has championed the idea that governments and other donors should try to make a vaccine as attractive to industry as the average drug market is…
Right now research and development for neglected vaccines occurs primarily through public-private partnerships, which have invigorated the field in the past half a decade. Nonprofit groups … channel money from donors into deals with biotech and pharma companies. Industry involvement is growing, says Ramaz Mitaishvili,MD Chief Executive Officer of the RM Global Health, “but it’s still not at the level one would like to see.” …
RMGH and Vitafarma presently has few pending applications for generic products with the Health authorities of many countries and with the FDA in the United States, several of which are additional to Vitafarma’s pending product list. Both companies are gambling that the shortage of vaccine might persuade the Food and Drug Administration to take the unusual step of letting a state import a vaccine.
Vitafarma, headquartered in Moscow,Russia, Vitafarma specializes in the production of sterile pharmaceutical products including small volume injectable solutions, which are used throughout the world to treat a wide range of disease areas.
Vitafarma is also developing several combination vaccines using an anchor component, as well as a new group of vaccines for bacterial and viral infections. Vitafarma was founded in 1996 and currently employs a highly skilled workforce of 100 people.
Vitafarma’s research and development is focused on generic drugs. These activities encompass a wide range of technologies for slow release of tablets and capsules, injectibles and others. During the last three years Vitafarma introduced into the post soviet market, and other markets an average of 5 products per annum.
Vitafarma, is Russia’s pharmaceutical company, with 80% of its sales inside Russia. New agreement can shift sale toward United States and Africa. RMGH offered to Vitafarma developing, manufacturing and marketing generic and branded human pharmaceuticals, active pharmaceutical ingredients, medical disposables and veterinary products.
Statements contained in this Press Release, other than statements of historical facts, are forward-looking statements subject to a number of uncertainties that could cause actual events or results to differ materially from some statements made.
Visit Vitafarma, on the Internet at www.vitafarma.ru Visit RM Global Health Inc., on the Internet at www.rmgh.net
For further information, please contact: Dr. Kevin Gardener, RM Global Health, Inc. Tel: (888) 427-5517 E-mail: [email protected]
Company details
If you want to find out more about the company visit RM Global Health Inc. profile.
